Cholangiocarcinoma Foundation Innovation Award
Three-year, USD 750,000 award to accelerate innovative clinical trials and novel therapies in cholangiocarcinoma, prioritizing designs and endpoints that can raise evidence levels and change clinical practice.
Eligibility Criteria:
-
Degrees: MD, PhD, PharmD, DVM (or equivalent).
-
Roles: Full/Associate Professor, Clinical Researcher, Research Scientist, Epidemiologist, Biostatistician, or Postdoctoral Fellow.
-
Institutions: Academic/medical/research institutions worldwide.
-
Collaboration: New or established multi-center teams (≥2 sites) with capability to complete the work.
-
Prior CCF awardees may apply; prior CCA experience not required.
Funding Details:
-
Total: USD 750,000 over 3 years (USD 250,000/year).
-
Direct project costs only; no indirect/overhead.
-
Supports PI salary/benefits and research expenses.
-
Areas of interest: basic, translational (human samples/data), and clinical science; topics include neoadjuvant/adjuvant trial designs, novel endpoints (e.g., downstaging), and robust evaluation of loco-regional therapies.
Deadline:
-
LOI due: August 22, 2025.
-
Invitations to apply: September 17, 2025.
-
Full application due: October 29, 2025.
-
Scientific review: November 20, 2025.
-
Award notification: November 24, 2025.
-
Earliest start: January 2026.
Where to Go for Further Information:
-
See the Call for Letters of Intent on the Cholangiocarcinoma Foundation website for LOI components (one-page summary & aims, references, NIH biosketch/CV) and full application instructions.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023